Replies to post #522667 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

LOL, we got to $2+ on anticipation of journal and now we are heading about a fake price ceiling when even more news might drop?! Nonsense

[Poor Man -]

A partnership is actually the next logical step to fund the company and set the conditions for a listing. A scientific journal article has no effect in and of itself to holding the ASM. I’m sure they must know a JA won’t hold much water with shareholders as the only rationale to increase the number of authorized shares. Imagine what that ugly scenario would look like!

Partnerships happen at all stages in the drug development cycle, and often include milestone payments. There’s no need to necessarily wait until an approval in the UK. If they were to wait, it would just mean more and substantial dilution — which they likely want to avoid.

Unless the MHRA is imminent, I just can’t see them putting the plane into a nose dive before entering into a JV or partnership of some sorts.

[NotSure2]

LOL!!! Finally I can comment on a way out of touch with reality comment that makes me on the bull side!!!

A Journal pub that is extremely good will bring us between $1.5 to $2.5 just by itself.

Same as flashwork aproval by itself. (Althought I would expect a steeper spike on JA before droping back steep as well to ~ $1.25/$1.75). As for flashwork, a slower but steadier spike over more days, that could go even to $3 or $4.

A combination of both? We might see the $5/$6 range.

Then waiting for any RA aproval to go higher.

But agree w you, I dont think we will see flashwork before end 2023, or mid 2024, way too many steps to complete. (I hope before obviously).